Why the study?
Patients with established stable CAD have varied smoking trajectories with unclear consequences on CV events, and the impact and timing of smoking cessation versus reduction needed clarification.
Does smoking cessation or reduction reduce the composite of cardiovascular death and MI in outpatients with stable coronary artery disease?
Does smoking cessation or reduction reduce the composite of cardiovascular death and MI in outpatients with stable coronary artery disease?
In patients with stable CAD, smoking cessation at any time significantly reduces cardiovascular risk, whereas merely reducing smoking quantity provides no cardiovascular benefit.
May support emphasizing complete cessation over reduction in stable CAD; leaves open randomized confirmation of benefit.
BACKGROUND AND AIMS: There is a variety of smoking habits trajectories in patients with established stable coronary artery disease (CAD), with unclear consequences on cardiovascular (CV) events. We aimed to clarify the impact of smoking cessation and reduction on long-term cardiovascular outcomes in stable CAD patients, evaluating whether quitting at any stage still provides significant benefits and to what extent. METHODS: The CLARIFY registry included 32,378 outpatients with stable CAD. Smoking history and status were recorded annually during the 5-year follow-up. In active smokers, we studied the effect of smoking cessation or reduction. In former smokers, we analysed the timing of smoking cessation relative to CAD diagnosis and residual CV risk based on years of abstinence. The primary outcome was a composite of CV death and MI. RESULTS: At inclusion, 46.2% of patients were former smokers and 12.5% current smokers. Amongst active smokers, smoking cessation in the stable phase of the disease was associated with improved outcomes, irrespective of timing (aHR 0.56, 95%CI 0.42-0.76, p<0.001). However, smoking quantity reduction was not associated with improved CV outcomes. Among former smokers, 55.7% had quit within a year of CAD diagnosis. Each additional year of smoking post-CAD diagnosis increased CV risk. Former smokers never returned to the CV risk level of never smokers, regardless of years of abstinence. CONCLUSIONS: In stable CAD patients, smoking cessation is associated with significantly better CV outcomes and survival, irrespective of timing of cessation, and should therefore always be a priority. Smoking reduction was not associated with improved CV outcomes. Most former smokers quit within a year of CAD diagnosis, and CV risk increase with each subsequent year of active smoking.
No takes yet. Share an insight, caveat, or question.
Mesnier et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: